Introduction {#Sec1}
============

Lungs are constantly exposed to a variety of particles, allergens, and airborne microbes. Remarkably, this nonstop exposure generally results in tolerance instead of inflammation. Lung dendritic cells (DCs) are key inducers of lung tolerance.^[@CR1]--[@CR4]^ The induction of peripheral tolerance by DCs at the steady state is an active process that promotes the generation of peripheral regulatory T cells (pT-regs).^[@CR5]^ Mice lack of pT-regs spontaneously developed T~H~2 pathologies at mucosal sites, e.g., allergic inflammation and asthma.^[@CR6]^ The induction of lung T-regs can reverse asthma in mice.^[@CR7],[@CR8]^

Lung DCs consist of functionally distinct subsets: the CD103^+^ conventional DC (cDC1), the CD11b^+^CD24^+^CD64^−^ conventional DC (cDC2), monocyte-derived CD11b^+^CD24^−^CD64^+^ DC (moDCs), and B220^+^SiglecH^+^CD11C^low^ plasmacytoid DCs (pDCs).^[@CR9]^ cDC2 itself is a heterogeneous population, including a subpopulation of Klf4^+^/Mgl2^+^ cells promoting T~H~2 responses.^[@CR10]--[@CR13]^ cDC1 and pDCs were reported to induce T-regs in the lung.^[@CR2],[@CR14]^ Lung Siglec F^+^ macrophage can also induce T-regs.^[@CR15]^ Thus, it remains unclear which lung antigen-presenting cells (APCs) induce the lung T-regs at steady state.

Lung DCs also promote immunogenic responses. Lung cDC1 promotes the antigen cross-presentation and the induction of cytotoxic T lymphocyte responses. Lung cDC2 require IRF4 expression for development and have been shown to mediate house dust mite (HDM)-induced asthma.^[@CR10],[@CR13],[@CR16],[@CR17],[@CR18]^ cDC2 also induces T~H~17,^[@CR19],[@CR20]^ T follicular helper (T~FH~) responses.^[@CR12],[@CR21]^ Noteworthy, the role of lung DCs to actively maintain lung tolerance at stead-state is exactly the opposite of the immunogenic roles during inflammation. It is unknown if there is a specific tolerogenic lung DC population or the same lung DC population promotes tolerogenic or immunogenic responses depending on the environmental cues.

Tolerogenic DCs induce T-regs by the expression of immunomodulatory molecules PD-L1/PD-L2, ICOS-L, and ILT3/4, and the production of immunosuppressive factors IL-10, TGFβ1, retinoic acid, and indoleamine 2,3-dioxygenase (IDO-1).^[@CR22]^ Among them, TGFβ1 likely plays a central role in DCs-induced long-term peripheral tolerance.^[@CR23]--[@CR25]^ TGF-β1 promotes the conversion of peripheral naive T cells to T-regs.^[@CR23]--[@CR25]^ Modanelli, G. et al.,^[@CR26]^ showed that TGFβ1-treated splenic DCs co-express IDO-1, arginase-1, and conferred long-term, immunosuppressive effects, which is essential for maintaining peripheral tolerance.^[@CR27]^ Whether this IDO-1^+^Arg-1^+^ TGFβ-1-producing DCs population exists in vivo, such as in the tolerogenic lung, is unknown.

Here, we sought to identify the lung tolerogenic DC population and its underlying mechanism that induces lung T-regs at steady state. Unexpectedly, we revealed the plasticity of lung DCs.

Results {#Sec2}
=======

Lung TNFR2^+^ cDC2 population maintains lung mucosal tolerance at steady state {#Sec3}
------------------------------------------------------------------------------

We reasoned that lung mucosal tolerance is actively maintained by a specialized lung DC population, and mice lacking this tolerogenic lung DC population will spontaneously lose lung mucosal tolerance. We first examined lung CD4^+^ T cells in mice lacking different DC subsets, Batf3^−/−^ (cDC1), IRF4^fl/fl^CD11c^cre^ (cDC2), and CCR2^−/−^ (moDCs). Only the IRF4^fl/fl^CD11c^cre^ mice had spontaneously increased CD4^+^ T cells in the lung (Fig. [1a](#Fig1){ref-type="fig"}). Furthermore, IRF4^fl/fl^CD11c^cre^ mice had enlarged mediastinal lymph nodes (medLNs), but relatively normal spleens (Fig. [1c, d](#Fig1){ref-type="fig"}) suggesting a selective loss of lung tolerance by the lack of cDC2.Fig. 1The lung TNFR2^+^ cDC2 population maintains lung tolerance and prevents lung inflammation at steady state.**a** Numbers of lung CD4^+^ T cells at steady state in C57BL/6 J (*n* = 7), Batf3^−/−^ (*n* = 6), CCR2^−/−^ (*n* = 4), and IRF4^fl/fl^CD11c^cre^ (*n* = 7) mice. Data were compiled from two independent experiments. **b** Numbers of lung CD4^+^ T cells in WT (*n* = 12), IRF4^fl/fl^CD11c^cre^ (*n* = 10), RelB^fl/fl^CD11c^cre^ (*n* = 7), and TNFR2^fl/fl^CD11c^cre^ (*n* = 5) mice at steady state. Data were representative of two independent experiments. **c** Image of mediastinal lymph nodes (mLNs; top) and spleens (bottom) in of 7- to 8-week-old knockout strains at steady state; *n* = 3 mice/group. Data are representative of two independent experiments. **d** Numbers of CD45^+^ cells in the lungs (left), mLNs (center), and spleens (right) in the indicated strains at steady state; *n* = 3 mice/group. Data were representative of two independent experiments. **e** Numbers of CD4^+^ T cells in IRF4^fl/fl^CD11c^cre^ mice 14 days post cell adoptive transfer. TNFR2^+^ or TNFR2^−^ cDC2 were sorted from WT mice lung and intranasally (i.n.) transferred into IRF4^fl/fl^CD11c^cre^ recipient mice; *n* = 4--6 mice/group. Data are representative of two independent experiments. **f** Numbers of lung Foxp3^+^CD4^+^ T-reg cells at steady state in C57BL/6 J, Batf3^−/−^, CCR2^−/−^, and IRF4^fl/fl^CD11c^cre^ mice; *n* = 4--5 mice/group. Data were representative of two independent experiments. Graphs represent the mean with error bars indication s.e.m. *P* values determined by one-way ANOVA Tukey's multiple comparison test. \**P* \< 0.05, \*\**P* \< 0.001, and \*\*\**P* \< 0.0001.

cDC2 is a heterogeneous population.^[@CR13],[@CR21]^ We reasoned that to actively maintain lung tolerance, the tolerogenic cDC2 subset may be constitutively activated. A subpopulation of lung cDC2, marked by expression of TNFR2, has constitutively activated RelB (pRelB; Supplementary Fig. [1a, b](#MOESM1){ref-type="media"}).^[@CR21]^ Notably, the TNFR2^+^ cDC2 (R2D2) population is the only lung DC subset that has constitutively activated RelB (Supplementary Fig. [1c](#MOESM1){ref-type="media"}). TNFR2^−/−^ mice lack the pRelB^+^ cDC2 subpopulation.^[@CR21]^ Furthermore, the R2D2 population expresses tolerogenic DC markers of PD-L1, PD-L2, Arg-1, and BTLA.^[@CR21]^ Last, the lack of RelB expression in DCs promotes the development of spontaneous allergic airway inflammation.^[@CR28]^ We thus generated RelB^fl/fl^CD11c^cre^ and TNFR2^fl/fl^CD11c^cre^ mice to examine their lung mucosal tolerance at steady state.

Similar to the IRF4^fl/fl^CD11c^cre^ mice, RelB^fl/fl^CD11c^cre^ and TNFR2^fl/fl^CD11c^cre^ mice had increased immune cells in the lung and medLNs, but not the spleen (Fig. [1b--d](#Fig1){ref-type="fig"}). The IRF4^fl/fl^CD11c^cre^, RelB^fl/fl^CD11c^cre^, and TNFR2^fl/fl^CD11c^cre^ mice may delete IRF4, RelB, and TNFR2 in other lung CD11c^+^ cells. We examined RelB, IRF4, and TNFR2 expression in these mice. We found that while RelB^fl/fl^CD11c^cre^ deleted RelB in alveolar macrophage (AM), IRF4, and TNFR2 expression in lung AM were intact in the IRF4^fl/fl^CD11c^cre^ or TNFR2^fl/fl^CD11c^cre^ mice (Supplementary Fig. [1d--f](#MOESM1){ref-type="media"}). Nevertheless, to exclude the possibility that the lack of IRF4, RelB, or TNFR2 in lung cells other than R2D2 cause spontaneous lung inflammation, we did the adoptive cell transfer experiment. We sorted out lung TNFR2^+^ (R2D2) and TNFR2^−^ cDC2 from C57BL/6 mice and adoptively transfer intranasally (i.n.) them into the IRF4^fl/fl^CD11c^cre^ recipient mice. The quality of the adoptive cell transfer was confirmed after 24 h (Supplementary Fig. [1g--i](#MOESM1){ref-type="media"}). After 2 weeks, IRF4^fl/fl^CD11c^cre^ mice receiving wild-type (WT) R2D2 cells had their lung CD4^+^ T cells numbers reduced, while the IRF4^fl/fl^CD11C^cre^ mice receiving the WT TNFR2^−^ cDC2 still had elevated numbers of lung CD4^+^ T cells (Fig. [1e](#Fig1){ref-type="fig"}). Together, these data strongly suggested that lung R2D2 population maintains lung mucosal tolerance at steady state.

Lung Mgl2^+^/IDO-1^+^ R2D2 population promotes lung T-regs induction at steady state {#Sec4}
------------------------------------------------------------------------------------

DCs promote tolerance via the generation of T-regs.^[@CR1]--[@CR4]^ We found that lung from IRF4^fl/fl^CD11c^cre^ had decreased T-regs at steady state (Fig. [1f](#Fig1){ref-type="fig"}). We reasoned that R2D2 cells induce T-regs in the lung. Intranasal administration of one dose of 1 µg innocuous protein antigens (e.g., OVA, PspA, H7N7-HA, and H1N1-NP) induces lung T-regs (Supplementary Fig. [2a](#MOESM1){ref-type="media"}). These lung T-regs were specific for the administered OVA antigen and neuropilin-1-negative pT-regs^[@CR29],[@CR30]^ (Supplementary Fig. [2b](#MOESM1){ref-type="media"}, [c](#MOESM1){ref-type="media"}). They also produce IL-10 (Supplementary Fig. [2d](#MOESM1){ref-type="media"}). Furthermore, intranasal administration of OVA turned adoptive transferred (i.v.) naive CD45.1^+^ T cells into Foxp3^+^ T-regs in vivo (Supplementary Fig. [1e](#MOESM1){ref-type="media"}). Last, consistent with the previous report,^[@CR3]^ blocking DC migration by anti-CCR7 monoclonal antibody (mAb) inhibited OVA-induced lung T-regs induction (Supplementary Fig. [1f](#MOESM1){ref-type="media"}).

The induction of lung T-regs by OVA depended on IRF4, RelB, or TNFR2 expression in CD11c^+^ cells but not Batf3, TNFR1, or CCR2 (Fig. [2a--c](#Fig2){ref-type="fig"}, Supplementary Fig. [2g](#MOESM1){ref-type="media"}). TNF2^fl/fl^LysM^cre^ mice, which delete TNFR2 in macrophage but not DCs (Supplementary Fig. [2h](#MOESM1){ref-type="media"}), had unaltered lung T-regs induction (Supplementary Fig. [2i](#MOESM1){ref-type="media"}). Last, adoptive transfer of R2D2 cells, but not lung TNFR2^−^ cDC2 increased lung T-regs induction in the IRF4^fl/fl^CD11c^cre^ mice (Fig. [2d](#Fig2){ref-type="fig"}). Notably, the rescue was incomplete and the likely due to technical difficulties (Supplementary Fig. [1i](#MOESM1){ref-type="media"} or other unknown contributors.Fig. 2Lung-resident Mgl2^+^/IDO1^+^ R2D2 population generates T-regs in the lung.**a** Flow cytometry plots (left) and quantification (right) of CD4^+^Foxp3^+^ T-reg cells in in WT, Batf3^−/−^, and IRF4^fl/fl^CD11c^cre^ mice treated with one dose of OVA (1 μg) intranasally (i.n.). Lungs were harvested on day 14; *n* = 4--6 mice/group. Data are representative of two independent experiments. **b**, **c** Flow cytometry plots (left) and quantification (right) of T-regs in TNFR2^fl/fl^CD11c^cre^ **b** and RelB^fl/fl^CD11c^cre^ mice **c** treated with one dose of OVA (1 μg) i.n. Lungs were harvested on day 14; *n* = 3--5 mice/group. Data are representative of two independent experiments. **d** IRF4^fl/fl^CD11c^cre^ mice were adoptively transferred (i.n.) with lung TNFR2^+^ and TNFR2^−^ cDC2 from WT mice lung and treated with one dose of OVA (1 μg) i.n. Flow cytometry analysis (left) and quantification (right) of T-regs at day 14; *n* = 3--6 mice/group. Data are representative of two independent experiments. **e**, **f** Flow cytometry analysis of TNFR2^+^ cDC2 at steady state. Data are representative of three independent experiments; *n* = 3 mice/group. **g** IRF4^fl/fl^CD11c^cre^ mice were adoptively transferred (i.n.) with lung Mgl2^+^TNFR2^+^ and Mgl2^−^TNFR2^+^ cDC2 and treated with one dose of OVA (1 μg) i.n. Flow cytometry analysis (left) and quantification (right) of T-regs at day 14; *n* = 3--4 mice/group. Data are representative of two independent experiments. Graphs represent the mean with error bars indication s.e.m. *P* values determined by one-way ANOVA Tukey's multiple comparison test **a**, **d**, **g** or unpaired student *t*-test **b**, **c**. \**P* \< 0.05, \*\**P* \< 0.001, and \*\*\**P* \< 0.0001.

R2D2 cells express tolerogenic DC markers of PD-L1 and Arg-1.^[@CR21]^ Closer examination found that a subpopulation of R2D2 expresses Mgl2 (Fig. [2e](#Fig2){ref-type="fig"}). The Mgl2^+^ R2D2 population is PD-L1^+^PD-L2^+^ILT3^+^Arg-1^+^ and constitutively express IDO-1 (Fig. [2e](#Fig2){ref-type="fig"}). Notably, all the IDO-1^+^ R2D2 cells are Mgl2^+^ and Arg1^+^ (Fig. [2f](#Fig2){ref-type="fig"}). The Mgl2^+^ DC population has been characterized before in the skin to promote T~H~2 responses or suppress T~FH~ response.^[@CR11],[@CR31]^ We then adoptively transferred (i.n.) lung Mgl2^+^R2D2 and Mgl2^−^R2D2 cells into the IRF4^fl/fl^CD11c^cre^ mice and examined their ability to induce lung T-regs. Only Mgl2^+^R2D2 generated lung T-regs in the IRF4^fl/fl^CD11c^cre^ mice (Fig. [2g](#Fig2){ref-type="fig"}). Taken together, the lung Mgl2^+^/IDO-1^+^ R2D2 population induces lung T-regs at steady state.

Constitutive TNFR2 signaling is required for the presence of R2D2 population in the lung at steady state {#Sec5}
--------------------------------------------------------------------------------------------------------

TNFR2^−/−^ mice lack the pRelB^+^ population.^[@CR21]^ Here, we found that TNFR2^fl/fl^CD11c^cre^, not the TNFR2^fl/fl^LysM^cre^ mice, lack the TNFR2^+^pRelB^+^ cDC2 (R2D2) population (Fig. [3a, b](#Fig3){ref-type="fig"}, Supplementary Fig. [3a](#MOESM1){ref-type="media"}). Thus, TNFR2 expression in DCs mediates pRelB activation. Notably, at steady state, lung cDC2 is the only TNFR2^+^ DCs population (Supplementary Fig. [3b](#MOESM1){ref-type="media"}). We hypothesized that there was an active TNFR2-pRelB signaling in the lung R2D2 population at steady state.Fig. 3Tonic TNFR2 signaling is required for the presence of the R2D2 population in the lung.**a**--**c** Flow cytometry analysis of TNFR2 **a** and pRelB expression **b** on lung cDC2 in TNFR2^fl/fl^ and TNFR2^fl/fl^CD11c^cre^ mice at steady state. WT mice were treated i.n. with anti-TNFR2 blocking antibody (20 μg) or TNFR2-Fc recombinant protein (2 μg). Lungs were harvested 24 h later; *n* = 3--4 mice/group. Data are representative of two independent experiments. **d** Quantification of Mgl2^+^TNFR2^+^ cDC2 in the lungs of indicated groups; *n* = 3--4 mice/group. Data are representative of two independent experiments. **e**, **f** Flow cytometry analysis of TNF expression by anti-TNF mAb (clone D2D4) **e** or mouse TNFR2-Fc recombinant protein **f**; *n* = 3 mice/group. Data are representative of three independent experiments. **g**--**h** Flow cytometry analysis of TNFR2^+^ cDC2 **g** and Ki67 expression **h** in mice treated i.n. with anti-TNFR2 mAb (TR75.89) and TNFR2-agonist TNF~D221N/A223R~ (1 μg). Lungs were harvested 24 h later; *n* = 3 mice/group. Data are representative of two independent experiments. Graphs represent the mean with error bars indication s.e.m. *P* values determined by one-way ANOVA Tukey's multiple comparison test **c**, **d** or unpaired student *t*-test **g**, **h**. \**P* \< 0.05, \*\**P* \< 0.001, and \*\*\**P* \< 0.0001.

Indeed, blocking TNFR2 signaling with anti-TNFR2 blocking mAb inhibited pRelB expression in cDC2 (Fig. [3b](#Fig3){ref-type="fig"}) and T-regs induction in the lung (Supplementary Fig. [3c](#MOESM1){ref-type="media"}). Unexpected, blocking TNFR2 dramatically decreased the numbers of lung TNFR2^+^ pRelB^+^ cDC2 (R2D2) at steady state (Fig. [3a--c](#Fig3){ref-type="fig"}). To exclude the possibility that the anti-TNFR2 blocking mAb may interfere with the TNFR2 detection by flow cytometry, we used the TNFR2-Fc (human IgG1) fusion protein to disrupt the TNFR2 interaction with its ligand in vivo. Again, TNFR2-Fc (human IgG1) reduced R2D2 population (Fig. [3a--c](#Fig3){ref-type="fig"}). Notably, in these experiments, the numbers of lung R2D2 cells showed a more dramatic reduction (Fig. [3c](#Fig3){ref-type="fig"}) than the percentage changes (Fig. [3a](#Fig3){ref-type="fig"}). Indeed, the total numbers of lung cDC2 cells decreased in the TNFR2^fl/fl^CD11c^cre^ mice, mice treated with anti-TNFR2 blocking mAb or TNFR2-Fc likely due to the loss of the R2D2 subpopulation in lung cDC2 subset.

We further examined the Mgl2^+^/IDO-1^+^ R2D2 population and found, as expected, that blocking TNFR2 or TNFR2-Fc treatment reduced the Mgl2^+^ R2D2 number by 90% (Fig. [3d](#Fig3){ref-type="fig"}). Thus, the lung R2D2, including the T-regs-inducing Mgl2^+^ R2D2 subset, depends on the constitutive TNFR2 signaling.

TNFR2 binds specifically to transmembrane TNF (tmTNF).^[@CR32]^ To identify TNF-expressing lung cells at steady state, we first did intracellular TNF staining to detect total cellular TNF, including tmTNF and soluble TNF. We found that the CD45^−^ lung cells were the main TNF^+^ lung cells at steady state (Fig. [3e](#Fig3){ref-type="fig"}). Next, we used the TNFR2-Fc (human IgG1) fusion protein to detected TNFR2 ligands, i.e., tmTNF. TNFR2 ligands were mainly on CD45^−^EP-CAM^+^ lung epithelial cells at steady state (Fig. [3f](#Fig3){ref-type="fig"}). We reasoned that, at steady state, tmTNF on lung epithelial cells engages TNFR2 on R2D2 to maintain its presence in the lung.

To mimic the effect of tmTNF that signals through TNFR2 specifically, we made a TNF~D221N/A223R~ mutant. The TNF~D221N/A223R~ mutant only binds to TNFR2,^[@CR33]^ thus serves as a TNFR2-specific agonist. TNF functions as a trimer.^[@CR34]^ TNF~D221N/A223R~ is a monomer. We, thus, aggregated TNFR2 in vivo with the nonblocking TNFR2 mAb followed by the addition of TNF~D221N/A223R~ to activate TNFR2 signaling. Intranasal administration of a nonblocking anti-TNFR2 mAb (TR75.89) and the TNF~D221N/A223R~ increased R2D2 population (Fig. [3g](#Fig3){ref-type="fig"}). Importantly, we found increased Ki67^+^ cells in the R2D2 population in mice treated with tmTNF (Fig. [3h](#Fig3){ref-type="fig"}), indicating the enhanced proliferation of R2D2 cells by TNFR2 engagement. As a negative control, intranasal administration of TNF~D221N/A223R~ did not enhance Ki67 expression in the cDC1 population, which do not express TNFR2 (Supplementary Fig. [3d](#MOESM1){ref-type="media"}).

In conclusion, the steady-state lung R2D2 population, including the Mgl2^+^/IDO-1^+^R2D2, is a specialized DC subset adapted to the lung microenvironment and needs the constitutive tmTNF-TNFR2 signaling for its existence.

Constitutive IFNAR1 signaling in Mgl2^+^R2D2 cells drives lung T-regs induction {#Sec6}
-------------------------------------------------------------------------------

IDO-1^+^, not IDO-1^−^, R2D2 cells induce lung T-regs. However, we found that intranasal administration of an anti-IFNAR1 blocking mAb inhibited T-regs induction in the lung (Fig. [4a](#Fig4){ref-type="fig"}), but did not affect IDO-1 expression in R2D2 cells (Supplementary Fig. [4a](#MOESM1){ref-type="media"}). Similarly, IFNAR1^−/−^ mice failed to generate lung T-regs in response to OVA (Fig. [4b](#Fig4){ref-type="fig"}) but retained the R2D2 population, including the Mgl2^+^ R2D2 (Supplementary Fig. [4b](#MOESM1){ref-type="media"}) population in the lung. Thus, IDO-1 or Mgl2 expression in R2D2 is not sufficient for T-regs induction. Rather, IFNAR1 signaling is critical.Fig. 4IFNβ-IFNAR1 signaling in iR2D2 cells promotes lung T-regs induction.**a** Flow cytometry analysis (left) and quantification (right) of lung TNFR2^+^ cDC2 in WT mice treated i.n. with isotype (20 µg) or anti-IFNAR1 blocking antibody (20 μg). Lungs were harvested 24 h later; *n* = 3--4 mice/group. Data are representative of three independent experiments. **b** Flow cytometry analysis (left) and quantification (right) of lung T-regs in WT treated i.n. with isotype (20 µg) or anti- IFNAR1 blocking antibody (20 μg) and one dose of OVA (1 μg) i.n. Lungs were harvested on day 14; *n* = 4--5 mice/group. Data are representative of three independent experiments. **c** Flow cytometry analysis of TNFR2^+^ cDC2 at steady state; *n* = 3 mice/group. Data are representative of two independent experiments. **d** IFNAR1^−/−^ mice were adoptively transferred (i.n.) with lung TNFR2^+^ cDC2 and one dose of OVA (1 μg) i.n. Flow cytometry analysis of T-regs on day 14; *n* = 3 mice/group. Data are representative of two independent experiment. **e** Flow cytometry analysis (left) and numbers (right) of T-regs in mice treated i.n. with OVA (1 μg) or IFNβ (200 ng). Lungs were harvested on day 14; *n* = 3--5 mice/group. Data are representative of two independent experiments. **f** Flow cytometry analysis (left) and absolute numbers (right) of T-regs in IRF4^fl/fl^ and IRF4^fl/fl^CD11c^cre^ mice treated i.n. with OVA (1 μg) or OVA (1 μg) and IFNβ (200 ng). Lungs were harvested on day 14; *n* = 3 mice/group. Data are representative of two independent experiments. **g** Numbers of Mgl2^+^TNFR2^+^ and Mgl2^−^TNFR2^+^ cDC2 in mice treated i.n. with PBS or IFNβ (200 ng); *n* = 3 mice/group. Data are representative of two independent experiment. **h**--**i** Flow cytometry analysis of IFNβ expression at steady state by the anti-IFNβ mAb (clone D2J1D); *n* = 3 mice/group. Data are representative of two independent experiments. Graphs represent the mean with error bars indication s.e.m. *P* values determined by one-way ANOVA Tukey's multiple comparison test **f** or unpaired student *t*-test **a**, **b**, **e**. \**P* \< 0.05, \*\**P* \< 0.001, and \*\*\**P* \< 0.0001.

R2D2 has the highest expression of IFNAR1 among lung DCs subsets (Supplementary Fig. [4c](#MOESM1){ref-type="media"}, [d](#MOESM1){ref-type="media"}) at steady state. In the R2D2 population, all IDO-1^+^ R2D2 cells express high IFNAR1 compared to the IDO-1^−^ R2D2 (Fig. [4c](#Fig4){ref-type="fig"}). Furthermore, steady-state R2D2 cells have elevated pSTAT1(Y701) signal that were further enhanced by intranasal IFNβ treatment but lost after anti-IFNAR1 treatment (Supplementary Fig. [4e](#MOESM1){ref-type="media"}).

To establish that R2D2 cell-intrinsic IFNAR1 signaling promotes lung T-regs induction, we adoptively transferred (i.n.) WT R2D2 into IFNAR1^−/−^ mice and treated the recipient mice with OVA. After 14 days, we found that IFNAR1^−/−^ mice receiving WT R2D2 cells restored T-regs induction in the lung (Fig. [4d](#Fig4){ref-type="fig"}). Thus, R2D2 cell-intrinsic IFNAR1 signaling is sufficient for lung T-regs induction.

Indeed, intranasal administration of IFNβ enhanced T-regs induction in the lung (Fig. [4e](#Fig4){ref-type="fig"}). Importantly, IFNβ did not induce T-regs in IRF4^fl/fl^CD11c^cre^ mice, suggesting IFNβ acts on cDC2 to induce T-regs (Fig. [4f](#Fig4){ref-type="fig"}). Interestingly, the intranasal administration of IFNβ did not increase the total number of lung R2D2 cells (Fig. [4g](#Fig4){ref-type="fig"}). Rather, IFNβ treatment tend to increase cell numbers of Mgl2^+^ R2D2, while decreased numbers of Mgl2^−^ R2D2 (Fig. [4g](#Fig4){ref-type="fig"}) suggesting IFNβ treatment in vivo may turn Mgl2^−^ into T-regs-inducing Mgl2^+^ R2D2. In light of the critical role of R2D2-intrinsic IFANR1 signaling in T-regs induction, we named the T-regs-inducing Mgl2^+^/IDO-1^+^ R2D2 as [I]{.ul}FNAR1^hi^ R2D2 (iR2D2).

Last, we wanted to determine the cellular source of IFNβ in the lung that generates iR2D2 at steady state. Using intracellular IFNβ stain, we found that at steady state, the Epcam^+^CD45^−^ lung epithelial cells were the sole IFNβ-producing cells (Fig. [4h](#Fig4){ref-type="fig"}). Intriguingly, only \~18% EPCAM^+^CD45^−^ lung epithelial cells were IFNβ^+^ suggesting a selected population of lung epithelial cells are responsible for IFNβ production at steady state (Fig. [4i](#Fig4){ref-type="fig"}).

IFNβ activates TGFβ1 in iR2D2 and drives lung T-regs induction {#Sec7}
--------------------------------------------------------------

How does the IFNAR1 signaling activate the tolerogenic program in the iR2D2 cells? pT-regs are generated by TGFβ1.^[@CR23]--[@CR25]^ R2D2 produced TGFβ1 in response to H7N7-HA (Fig. [5a](#Fig5){ref-type="fig"}). Neutralizing total TGFβ1 led to the loss of T-regs induction in the lung (Fig. [5b](#Fig5){ref-type="fig"}).Fig. 5IFNβ-IFNAR1-TGFβ1 signaling axis in iR2D2 promotes lung T-regs induction.**a** Flow cytometry analysis of TNFR2^+^ cDC2 treated i.n. with PBS or H7N7-HA (1 μg). Lungs were harvested 24 h later; *n* = 3 mice/group. Data are representative of two independent experiments. **b** Flow cytometry analysis (left) and numbers (right) of T-regs in mice treated with PBS, OVA (1 μg)/isotype control, or OVA (1 μg) and anti-TGFβ1 neutralizing antibody (75 μg); *n* = 3--4 mice/group. Lungs were harvested on day 14. Data are representative of two independent experiments. **c** Flow cytometry analysis of TGFβ1 production by TNFR2^+^ cDC2 in mice treated i.n. with PBS, OVA (1 μg), or OVA (1 μg) and IFNβ (200 ng). Lungs were harvested 24 h later; *n* = 3 mice/group. Data are representative of three independent experiments. **d** Flow cytometry analysis of TGFβ1 production by TNFR2^+^ cDC2 in mice treated with PBS, OVA (1 μg)/isotype control, or OVA (1 μg) and anti-IFNAR1 blocking antibody (20 μg). Lungs were harvested 24 h later; *n* = 3 mice/group. Data are representative of two independent experiments. **e** Experimental design for adoptive transfer. **f**--**g** IFNAR1^−/−^ mice were adoptively transferred (i.n.) with lung TNFR2^+^ cDC2 and treated with PBS or IFNβ (200 ng). Flow cytometry analysis of TGFβ1 production by TNFR2^+^ cDC2 **f** and T-regs **g**; *n* = 3 mice/group. Data are representative of two independent experiments. Graphs represent the mean with error bars indication s.e.m. *P* values determined by unpaired student *t*-test **b**, **f**, **g**. \**P* \< 0.05, \*\**P* \< 0.001, and \*\*\**P* \< 0.0001.

The induction of TGFβ1 in R2D2 depends on IFNβ-IFNAR1 signaling. Intranasal administration of IFNβ increased TGFβ1 in R2D2 (Fig. [5c](#Fig5){ref-type="fig"}), while anti-IFNAR1 blocking mAb inhibited OVA-induced TGFβ1 production by R2D2 (Fig. [5d](#Fig5){ref-type="fig"}). Notably, anti-IFNAR1 mAb did not affect OVA-induced TGFβ1 production in cDC1, moDCs, or AMs (Supplementary Fig. [5a](#MOESM1){ref-type="media"}). Block IFNAR1 inhibited OVA-induced T-regs induction (Fig. [4a](#Fig4){ref-type="fig"}). Thus, TGFβ1 production by cDC1, AM, or moDCs were not sufficient for the induction of T-regs in the lung.

To establish that IFNβ acted on R2D2 to induce TGFβ1 expression, we adoptively transferred (i.n.) the lung R2D2 cells from the CD45.1^+^ mice into IFNAR1^−/−^ mice and treated (i.n.) the recipient IFNAR1^−/−^ mice with IFNβ (Fig. [5e](#Fig5){ref-type="fig"}). We found that IFNβ administration induced TGFβ1 in the transferred CD45.1^+^ cells (Fig. [5f](#Fig5){ref-type="fig"}). Furthermore, IFNβ restored T-regs induction in the IFNAR1^−/−^ mice received CD45.1^+^ R2D2 cells (Fig. [5g](#Fig5){ref-type="fig"}), suggesting that IFNβ acted on lung R2D2 cells to generate TGFβ1 and lung T-regs induction. Taken together, IFNAR1 signaling in iR2D2 produces TGFβ1 and induces T-regs in the lung.

R2D2 cells promote T~H~2 responses in HDM-induced asthmatic mice {#Sec8}
----------------------------------------------------------------

cDC2 mediates HDM-induced asthma.^[@CR13],[@CR16],[@CR18]^ Recent studies indicated that a Klf4^+^/Mgl2^+ [@CR13]^, RelB^+^ cDC2 subset^[@CR10]^ mediates HDM-induced T~H~2 responses. iR2D2 expresses Mgl2, RelB. We suspected that the lung R2D2 population may be plastic and promote T~H~2 response in HDM-induced asthma.

First, we generated the HDM-induced asthmatic mice (Fig. [6a](#Fig6){ref-type="fig"}). HDM-treated mice generated HDM-specific IgE and IgG1 (Supplementary Fig. [6a](#MOESM1){ref-type="media"}), lung inflammation determined by hematoxylin and eosin (H&E) stain (Supplementary Fig. [6b](#MOESM1){ref-type="media"}), eosinophils infiltration in the lung (Supplementary Fig. [6c](#MOESM1){ref-type="media"}), and T~H~2 dominant cytokines in draining LNs (Supplementary Fig. [6d](#MOESM1){ref-type="media"}). Next, we examined the iR2D2 population in the asthmatic mice. We found increased numbers of total R2D2 cells in the asthmatic cells (Fig. [6b](#Fig6){ref-type="fig"}). The Mgl2^+^/IDO-1^+^ R2D2 population increased as well in the HDM-induced asthmatic mice (Fig. [6c](#Fig6){ref-type="fig"}, Supplementary Fig. [6e](#MOESM1){ref-type="media"}). However, no T-regs were generated in HDM mice (Fig. [6d](#Fig6){ref-type="fig"}). The R2D2 cells from HDM-induced mice also downregulated tolerogenic markers PD-L1, PD-L2, and, critically, IFNAR1 expression (Fig. [6e](#Fig6){ref-type="fig"}). In contrast, R2D2 cells from the HDM mice increased immunogenic markers OX40L, ICOSL, and T1/ST2 (Fig. [6f](#Fig6){ref-type="fig"}).Fig. 6R2D2 promotes T~H~2 responses in HDM mice.**a** Experimental protocol for HDM-induced acute asthma. **b** Flow cytometry analysis (left) and numbers (right) of TNFR2^+^ cDC2 in PBS or HDM-induced asthmatic WT mice; *n* = 2--4 mice/group. Data were compiled from two independent experiments. **c** Flow cytometry analysis of Mgl2^+^TNFR2^+^ cDC2 in PBS or HDM-induced asthmatic WT mice; *n* = 4--5 mice/group. Data are representative of three independent experiments. **d** Flow cytometry analysis of T-regs in OVA (1 µg) treated (left) and HDM-induced asthmatic WT mice (right); *n* = 3 mice/group. Data are representative of three independent experiments. **e**--**f** Flow cytometry analysis of TNFR2^+^ cDC2 in HDM-induced asthmatic WT mice; *n* = 3 mice/group. Data are representative of three independent experiments. **g** Experimental design for adoptive transfer (top). Flow cytometry analysis of IL-4 production by lung CD4^+^ T cells; *n* = 3mice/group. Data are representative of two independent experiments. **h** Flow cytometry analysis of R2D2 in OVA (1 µg) treated (left) and HDM-induced asthmatic WT mice (right); *n* = 3 mice/group. Data are representative of three independent experiments. Graphs represent the mean with error bars indication s.e.m. *P* values determined by unpaired student *t*-test **b**. \**P* \< 0.05, \*\**P* \< 0.001, and \*\*\**P* \< 0.0001.

Last, adoptive transfer (i.n.) R2D2 from HDM mice into naive mice generated T~H~2 response in vivo (Fig. [6g](#Fig6){ref-type="fig"}), which was different from the T-regs-inducing R2D2 at steady state (Fig. [2d](#Fig2){ref-type="fig"}). Comparing the tolerogenic R2D2 (iR2D2) from OVA-treated mice with the T~H~2-promoting R2D2 from the HDM mice, the tolerogenic R2D2 expresses TGFβ1 while the immunogenic R2D2 expresses IL-4 and IL-4/TGFβ1 (Fig. [6h](#Fig6){ref-type="fig"}). We concluded that the lung R2D2 population is plastic and can promote T-regs or T~H~2 responses depending on the environmental cue, e.g., IFNβ or HDM.

Human lungs have a phenotypically similar plastic iR2D2 population {#Sec9}
------------------------------------------------------------------

We reasoned that healthy human lung should have a functionally similar tolerogenic DC subset. Little is known about human lung cDC2 subsets in healthy individuals or patients. We sampled healthy donor lungs that were transplanted into lung patients and identified the same TNFR2^+^pRelB^+^IDO-1^+^PD-L1^+^PD-L2^+^ cDC2 population in the healthy human lungs (Fig. [7a](#Fig7){ref-type="fig"}, Supplementary Fig. [7a, b](#MOESM1){ref-type="media"}). The healthy human lung iR2D2 cells constitutively express TGFβ1 and Arg-1 (Fig. [7b](#Fig7){ref-type="fig"}) as well.Fig. 7Lung TNFR2^+^ cDC2 in healthy and lung diseases patients.**a** Flow cytometry analysis of pulmonary cDC2 subpopulation in healthy human lungs. Data are representative of eight independent experiments. **b** Flow cytometry analysis of TNFR2^+^cDC2 in donor, emphysema, and chronic-rejected human lungs. Data are representative of three independent experiments. **c** Frequency of TNFR2^+^ cDC2 in diseased human lungs. Data were compiled from multiple independent experiments. Graphs represent the mean with error bars indication s.e.m.

We also identified IDO-1^+^ R2D2 population in lung explants from emphysema, interstitial lung disease patients (Fig. [7c](#Fig7){ref-type="fig"}). However, R2D2 cells from lung patients had decreased TGFβ1, Arg-1, and PD-L1, but increased IL-4 expression (Fig. [7b](#Fig7){ref-type="fig"}) similar to the R2D2 from the asthmatic mice. Notably, lung explants from chronic obstructive pulmonary disease patients had very little R2D2 cells (Fig. [7c](#Fig7){ref-type="fig"}). We conclude that the phenotypically similar R2D2 cells can be found in healthy human lungs and some lung disease patients.

Discussion {#Sec10}
==========

Here, we identified a lung iR2D2 as the tolerogenic DC generating lung T-regs and preventing lung inflammation at steady state. Our conclusion is based exclusively on studies in the lung in vivo. Our conclusion is different from previous reports, suggesting pDCs,^[@CR2]^ cDC1^[@CR14]^, or macrophage^[@CR15]^ induces T-regs in the lung. We showed that mice lacking the iR2D2 population by gene ablation or antibody depletion failed to generate lung T-regs, while intranasal administration of IFNβ induced R2D2-dependent lung T-regs. Notably, the data present here could not exclude a role for lung macrophage in inducing lung T-regs. Thought it is unlikely macrophage direct prime T cells, lung macrophage could cooperate with R2D2 to generate T-regs in the lung.^[@CR15]^

The lung iR2D2 population is plastic. iR2D2 is a subpopulation of cDC2. Previous studies established that cDC2 mediates T~H~2,^[@CR10],[@CR13],[@CR16]^ T~H~17^[@CR19],[@CR20]^ responses. Meanwhile, Mellman's group showed that IRF4^fl/fl^CD11c^cre^ mice had impaired peripheral tolerance.^[@CR35]^ Most recently, Berlin's group identified a PD-L2^+^CD11b^+^ dermal DCs that can elicit T~H~2 responses or prime T-regs.^[@CR36]^ We also showed that R2D2 promotes T~H~ responses of the mucosal adjuvant cyclic di-GMP in vivo*.*^[@CR21]^ We propose that DCs at the barrier surface, influenced by their microenvironment, are plastic-inducing T-regs, maintaining peripheral tolerance at steady state but promoting immunogenic responses during pathogenic conditions. Indeed, Agace's group showed that CD103^+^ DCs in the gut has a dual role in tolerogenic and immunogenic T-cell responses.^[@CR4]^

The tolerogenic iR2D2 population is a product of two constitutive signals from its microenvironment: IFNβ-IFNAR1 and tmTNF-TNFR2. IFNβ promote T-regs in the gut.^[@CR37]^ Using a TNFR2 agonist, we showed that TNFR2 signaling promoted R2D2 proliferation. TNFR2 expression defines a highly immunosuppressive T-regs found in tumor microenvironment promoting cancer cell survival and tumor growth.^[@CR38]^ Similar to our R2D2 cells, TNFR2 activation stimulates the proliferation of TNFR2^+^ T-regs.^[@CR39]^ Antagonistic antibodies against human TNFR2 inhibited TNFR2^+^ T-regs proliferation.^[@CR39]^ The underlying molecular mechanism of TNFR2 signaling induced cell proliferation is unknown.

R2D2 cells with active IFNAR1 signaling become iR2D2. iR2D2 intrinsic IFNβ signaling is necessary and sufficient for lung T-regs induction and the production of TGFβ1. However, the molecular pathway by which IFNβ-IFNAR1 signaling leading to TGFβ1 production is unknown. IFNβ has an immunomodulatory effect. In the clinic, IFNβ (Avonex®, Rebif®) has been used to treat relapsed multiple sclerosis for over 20 years. Nevertheless, the in vivo mechanism and targeted cells of IFNβ treatment remain poorly defined.^[@CR40]^ We propose that lung R2D2 or R2D2-like cells in other peripheral organs^[@CR41]^ are the effector cells for the immunomodulatory function of IFNβ in vivo. Noteworthy, IFNα is not approved for multiple sclerosis. Future studies should also determine if IFNβ activates a unique IFNAR1 signaling^[@CR42]^ in iR2D2 cells to control the tolerogenic program at steady state.

Lung epithelial cells are a major source of tmTNF and the sole producer of lung IFNβ at the steady state. Impaired bronchial epithelial cells (BECs) IFNβ production has been well documented in asthmatic patients.^[@CR43]^ We thus propose a new paradigm that at steady state, lung epithelial cells express tmTNF to keep R2D2 alive and continuously secret IFNβ to condition R2D2 to generate lung T-regs and prevent lung inflammation (Fig. [8](#Fig8){ref-type="fig"}). Different from the current lung-epithelial cells-DCs-T~H~2 axis during inflammation,^[@CR44]^ the lung epithelial cells IFNβ-iR2D2-T-regs axis here is tolerogenic and needed to be constitutively active. Loss of tmTNF or IFNβ will result in the loss of iR2D2 and lung mucosal tolerance. Indeed, BECs from asthma patients are biased toward higher Thymic stromal lymphopoietin (TSLP) and lower IFNβ production.^[@CR45]^ Commensal microbiota drive tonic IFNβ production by lung epithelial cells that protect host from respiratory viral infection.^[@CR46],[@CR47]^ It is worth investigating if commensal microbiota can also protect host from asthma by driving lung IFNβ and enhancing steady-state lung mucosal tolerance.Fig. 8Model.Lung epithelium IFNβ/iR2D2/T-regs axis controls lung tolerance at steady state.

The plasticity of R2D2 cells makes them an ideal immunotherapy target for chronic inflammatory diseases. We showed that IFNβ administration could enhance lung T-regs induction. A phase II clinical trial of inhaled IFNβ for virus-induced asthma exacerbation showed promising results (clinicaltrials.gov, identifier NCT 01126177).^[@CR48],[@CR49]^ Translationally, targeting IFNβ directly to R2D2 will limit the toxicity of IFNβ and improve its efficacy. On the other hand, for studies exploring the therapeutic potential of ex vivo generated tolerogenic DCs, caution should be taken. Due to the plasticity of tolerogenic DCs, these ex vivo generated tolerogenic DCs maybe plastic and could be reconditioned by the inflammatory milieu and become immunogenic in vivo.

In summary, we identified iR2D2 as the tolerogenic lung DC population and surprisingly found it is plastic. This newly discovered DC plasticity can lead to novel anti-inflammatory therapy for lung diseases.

Methods {#Sec11}
=======

Key resources table {#Sec12}
-------------------

  Reagent or resource                                                        Source                                 Identifier
  -------------------------------------------------------------------------- -------------------------------------- ---------------------------
  Antibodies                                                                                                        
   Anti-mouse CD4-PE/Cy7 (clone: GK1.5)                                      BioLegend                              Cat. \#100422
   Anti-mouse IFNγ-PerCP/Cy5.5 (clone: XMG1.2)                               BioLegend                              Cat. \#505822
   Anti-mouse IL-4-APC (clone: 11B11)                                        BioLegend                              Cat. \#504106
   Anti-mouse IL-17a-PE (clone: TC11-1810.1)                                 BioLegend                              Cat. \#506903
   Anti-mouse CD44-Alexa Fluor 700 (clone: IM7)                              BioLegend                              Cat. \#103025
   Anti-mouse CD45-PercP/Cy5.5 (clone: 30-F11)                               Biolegend                              Cat. \#103131
   Anti-mouse Foxp3-Pacific Blue (clone: MF-14)                              BioLegend                              Cat. \#26410
   Anti-mouse MHCII(I-A/I-E)-Brilliant Violet 421 (clone: M5/114.15.2)       BioLegend                              Cat. \#107636
   Anti-mouse MHCII(I-A/I-E)-Alexa Fluor (clone: M5/114.15.2)                BioLegend                              Cat. \#107622
   Anti-mouse CD11c-APC/Cy7 (clone: N418)                                    Biolegend                              Cat. \#117323
   Anti-mouse/human CD11b-PE/Cy7 (clone: M1/70)                              BioLegend                              Cat. \#101216
   Anti-mouse/human CD11b-Brilliant Violet 605 (clone: M1/70)                BioLegend                              Cat. \#101237
   Anti-mouse CD64-PerCP/Cy5.5 (clone: X54-5/7.1)                            BioLegend                              Cat. \#139307
   Anti-mouse TNFR2-PE (clone:TR75-89)                                       BioLegend                              Cat. \#113405
   Anti-mouse TNFR2-APC (clone: REA228)                                      Miltenyi Biotec                        Cat. \#130-104-698
   Anti-mousPDL1-Brilliant Violet 421 (clone: 10F.9G2)                       BioLegend                              Cat. \#124315
   Anti-mouse PDL2-APC (clone: TY25)                                         BioLegend                              Cat. \#107210
   Anti-mouse/human Arg1-FITC                                                RD systems                             Cat. \#IC5868F
   Anti-mouse ILT3-PE (clone: H1.1)                                          BioLegend                              Cat. \#144904
   Anti-mouse IDO1-Alexa Fluor (clone: 2E2/IDO1)                             BioLegend                              Cat. \#654003
   Anti-mouse/human pRelB-PE (clone: D41B9)                                  Cell Signaling Technology              Cat. \#:13567
   Anti-mouse/human pSTAT1 (clone: 58D6)                                     Cell Signaling Technology              Cat. \#:9167
   Anti-mouse EPCAM-PerCP/Cy5.5 (clone: G8.8)                                BioLegend                              Cat. \#118219
   Anti-mouse/human Ki67-PE (clone: 11F6)                                    BioLegend                              Cat. \#151209
   Anti-mouse IFNAR1-APC (clone: MAR1-5A3)                                   BioLegend                              Cat. \#127313
   Anti-mouse IFNβ-Primary (clone:D2J1D)                                     Cell Signaling Technology              Cat. \#:974505
   Anti-mouse TNF-Primary (clone:D2D4)                                       Cell Signaling Technology              Cat. \#:11948
   Anti-mouse LAP (TGFβ1)-Brilliant Violet 421 (clone:TW7-16B4)              BioLegend                              Cat. \#141407
   Anti-mouse LAP (TGFβ1)-FITC (clone:TW7-16B4)                              BioLegend                              Cat. \#141413
   Anti-mouse CD45.1-APC (clone: A20)                                        BioLegend                              Cat. \#110713
   Anti-mouse OX40L-PE (clone: RM134L)                                       BioLegend                              Cat. \#108805
   Anti-mouse ICOSL-PE (clone: HK5.3)                                        BioLegend                              Cat. \#107405
   Anti-mouse T1ST2-APC (clone: D1H4)                                        BioLegend                              Cat. \#146605
   Anti-mouse IRF4-APC (clone: IRF4.3E4)                                     BioLegend                              Cat. \#646407
   Anti-human TNFR2-APC (clone: 3G7A02)                                      BioLegend                              Cat. \#358405
   Anti-human HLA-DR-APC/Cy7 (clone: L243)                                   BioLegend                              Cat. \#307617
   Anti-human PDL1-Brilliant Violet 421 (clone:29E.2A3)                      BioLegend                              Cat. \#329713
   Anti-human PDL2-PE (clone: 24F.10C12)                                     BioLegend                              Cat. \#329605
   Anti-human IDO1-Primary                                                   R&D Systems                            Cat. \#MAB6030
   Anti-human TGFβ1-PE (clone: Tw4-2F8)                                      BioLegend                              Cat. \#349603
   Anti-human Arginase 1-PE (clone: 14D2C43)                                 BioLegend                              Cat. \#369703
   Anti-human IL-4-PE (clone: G077F6)                                        BioLegend                              Cat. \#355003
   Anti-mouse F4/80-PerCP/Cy5.5 (clone: BM8)                                 BioLegend                              Cat. \#123127
   I-A(b) chicken ova 325-335 QAVHAAHAEIN APC-labeled tetramer               NIH Tetramer Core Facility             
   I-A(b) human CLIP 87-101 PVSKMRMATPLLMQA (control) APC-labeled tetramer   NIH Tetramer Core Facility             
   Anti-mouse Neuropilin-APC (clone: 3E12)                                   BioLegend                              Cat. \#145205
   Anti-human CD1c-PE/Cy7 (clone: L161)                                      BioLegend                              Cat. \#331515
   Anti-human CD14-PerCP/Cy5.5 (clone: 63D3)                                 BioLegend                              Cat. \#367109
   Anti-human CD206-FITC (clone: 15--2)                                      BioLegend                              Cat. \#321103
   Anti-CCR7 monoclonal antibody                                             R&D Systems                            Cat. \#MAB34477
   Anti-TNFR2 monoclonal antibody (clone: TR75--54.7)                        BioXcell                               Cat. \#BE0247
   Anti-TNFR2 monoclonal antibody (clone: TR75--32.4)                        Biolegend                              Cat. \#113202
   Isotype control (clone HTK888)                                            Biolegend                              Cat. \#400931
   Anti-TGFβ1 neutralizing antibody (19D8)                                   Biolegend                              Cat. \#521707
   Anti-IFNAR1 monoclonal antibody (clone: MAR1-5A3)                         Biolegend                              Cat. \#127303
   Anti-rabbit IgG (H+L), F(ab′)~2~ fragment-PE                              Cell Signaling Technology              Cat. \#:79408
   Anti-mouse IgG1-HRP                                                       Southern Biotech                       Cat. \#1030-05
   Anti-mouse IgE-HRP                                                        Southern Biotech                       Cat. \#1110-05
  Chemicals, peptides, and recombinant proteins                                                                     
   Cell Activation Cocktail with Brefreldin A                                Biolegend                              423303
   OVA                                                                       Invivogen                              Cat. \#vac-pova
   TNFR2-Fc (human IgG1) fusion protein                                      SinoBiological                         Cat. \#50128-M02H
   TNFR2-agonist (TNF~D221N/A223R~)                                          Creative® Biolabs                      Custom made
   Recombinant murine IFNβ                                                   R&D                                    Cat. \#8234-MB/CF
   House dust mites *Dermatophagoides pteronyssinus* (HDM-Der p1)            Greer Laboratories                     Cat. \#XPB82D3A2.5
  * Dermatophagoides farinae* (HDM-Der f1)                                   Greer Laboratories                     Cat. \#XPB81D3A2.5
   PspA                                                                      BEI Resources, NIAID, NIH              NR-33178
   H7N7-HA                                                                   BEI Resources, NIAID, NIH              NR-2633
   H1N1-NP                                                                   SinoBiological                         Cat. \#11675-V08B
   Foxp3/Transcription Factor Staining Buffer Set                            EBioscience                            Cat. \#00-5523-00
  Experimental models: organisms/strains                                                                            
   Mouse: IRF4^fl/fl^                                                        Jackson Laboratory                     Cat. \#009380
   Mouse: CD11c^Cre^                                                         Jackson Laboratory                     Cat. \#008068
   Mouse: Batf3^−/−^                                                         Jackson Laboratory                     Cat. \#013596
   Mouse: CCR2^−/−^                                                          Jackson Laboratory                     Cat. \#004999
   Mouse: RelB^fl/fl^                                                        Jackson Laboratory                     Cat. \#028719
   Mouse: TNFR2^fl/fl^ \[C57BL/6-Tnfrsf1b\<tm1c(EUCOMM)Wtsi\>/Ics\]          EMMA---European Mouse Mutant Archive   Cat. \#05925
   Mouse: IL-10^eGFP^                                                        Jackson Laboratory                     Cat. \#014530
   Mouse: TNFR1^−/−^                                                         Jackson Laboratory                     Cat. \#003243
   Mouse: IFNAR1^−/−^                                                        Jackson Laboratory                     Cat. \#028288
   Mouse: CD45.1                                                             Jackson Laboratory                     Cat. \#002014
   Mouse: Lysm^cre^                                                          Jackson Laboratory                     Cat. \#004781
  Software and algorithms                                                                                           
   FlowJo version 10.1r1                                                     FlowJo                                 <http://www.flowjo.com>
   Prism6                                                                    GraphPad                               <http://www.graphpad.com>

### Mice {#Sec13}

Age- and gender-matched mice (8--18-weeks old) were used for all experiments. C57BL/6, B6.CD45.1, *Batf3*^−/−^, *CCR2*^−/−^, *IL-10*^*GFP*^, *IRF4*^*fl/fl*^, *RelB*^*fl/fl*^, *IFNAR1*^−/−^, *CD11c*^*cre*^, *LysM*^*cre*^, and *TNFR1*^−/−^ mice on C57BL/6 background were purchased from The Jackson Laboratory. *TNFR2*^*fl/fl*^ mice were from the Euorpean Conditional Mouse Mutagenesis Program. Mice were housed and bred under pathogen-free conditions in the Animal Research Facility at the University of Florida. All mouse experiments were performed by the regulations and approval of the Institutional Animal Care and Use Committee at the University of Florida, IACUC number 201909362.

### Reagents {#Sec14}

Anti-TNFR2 monoclonal antibody (20 µg, TR75-54.7, BioXcell or TR75-32.4, BioLegend), anti-IFNAR1 monoclonal antibody (20 µg, MAR1-5A3, BioLegend), isotype control (20 µg HTK888, BioLegend), anti-TGFβ1 neutralizing antibody (75 µg, 19D8, BioLegend), anti-IFNβ monoclonal antibody (D2J1D, Cell Signaling, cat. no. 97450), TNFR2-Fc (human IgG1) fusion protein (2 µg, SinoBiological, cat. no. 50128-M02H), or TNF~D221N/A223R~ (1 µg, custom made by Creative® Biolabs) were administered i.n. in 40 µl phosphate-buffered saline (PBS). Recombinant mouse IFNβ (200 ng, \~240,000 IU; R&D, cat. no. 8234-MB/CF) was administered i.n. in 40 µl PBS.

The following reagent was obtained through BEI Resources, NIAID, NIH: *Streptococcus pneumoniae* family 2, clade 3 pneumococcal surface protein A (PspA UAB099) with C-terminal histidine tag, recombinant from *Escherichia coli*, NR-33179. H7 hemagglutinin (HA) protein from influenza virus, A/Netherlands/219/2003 (H7N7), recombinant from baculovirus, NR-2633. H1N1-NP was from SinoBiological (cat. no. 11675-V08B). Endotoxin-free OVA was from Invivogen (cat. no. vac-pova).

### HDM-induced asthma {#Sec15}

HDMs *Dermatophagoides pteronyssinus* (HDM-Der p1, Greer Laboratories, cat. no. XPB82D3A2.5) or *Dermatophagoides farinae* (HDM-Der f1, Greer Laboratories, cat. no. XPB81D3A2.5) was suspended in endotoxin-free PBS at a concentration of 5 mg/ml. HDM was freshly prepared by mixing equal parts of HDM-Der p1 and HDM-Der f1 in PBS. To induce asthma, mice were sensitized i.n. with three daily doses of 1 µg HDM on days 0--2 and were later challenged with 10 µg of HDM i.n. on days 9--13. BAL fluid, blood, lungs, and medLNs were collected on day 16. BAL fluid was collected in 0.7--1 ml PBS and blood was collected through cardiac puncture.

### Lung histology {#Sec16}

Lungs were fixed in 10% formalin, paraffin embedded, and cut into 4-µm sections. Lung sections were then stained for H&E. All staining procedures were performed by the histology core at the University of Florida.

### Isolation of lung cells {#Sec17}

Cells were isolated from the lung as previously described.^[@CR21]^ The lungs were perfused with ice cold PBS and removed. Lungs were digested in DMEM containing 200 μg/ml DNase I (Roche, 10104159001), and 25 μg/ml Liberase TM (Roche, 05401119001) at 37 °C for 2 h. Red blood cells were then lysed and a single cell suspension was prepared by filtering through a 70-µm cell strainer.

### HDM ELISA {#Sec18}

HDM-specific IgG1 and IgE were measured by enzyme-linked immunosorbent assay (ELISA) in the serum of HDM-treated mice. Secondary Abs used were anti-mouse IgG1-HRP (Southern Biotech, cat. no.1070--05) and anti-mouse IgE-HRP (Southern Biotech, cat. no.1110--05). To measure HDM-specific T-cell responses, lung cells were restimulated with 25 µg/ml of HDM for 4 days. IL-5 cytokines were measured in the supernatant by ELISA.

### Flow cytometry {#Sec19}

Single cell suspensions were stained with flourescent-dye-conjugated antibodies in PBS containing 2% fetal bovine serum and 1 mM EDTA. Surface stains were performed at 4 °C for 20 min. For intracellular cytokine or transcription factor stainings of murine and human cells, cells were fixed and permeabilized with the Foxp3 staining buffer set (eBioscience, cat. no 00-5523-00). CD4^+^FoxP3^+^ T-regs in the lung were analyzed 2 weeks after the treatment. Data were acquired on a BD LSRFortessa and analyzed using FlowJo software package (FlowJo, LLC). Cell sorting was performed on the BD FACSAriaIII Flow Cytometer and Cell Sorter.

### Adoptive transfer {#Sec20}

cDC2 subpopulations were sorted from the lungs of naive or HDM-treated mice with a FACSAriaIII flow cytometer. cDC2 were identified as MHCII^+^CD11c^+^ CD11b^+^ CD64^−^. cDC2 subsets were defined as MHCII^+^CD11c^+^CD11b^+^TNFR2^+^ and MHCII^+^CD11c^+^ CD11b^+^ TNFR2^−^.^[@CR21]^ A total of 500,000 cells were administered i.n. into recipient mice. DCs in the lungs were analyzed 24 h later. T cells in the lung were analyzed 14 days later.

Human lung explants {#Sec21}
-------------------

Human lung explants were procured at the Lung Transplant Center, Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Florida. Donor and patients consent for a research protocol (UF Lung Transplant Tissue/Databank (IRB201501133)). Healthy donor lungs were surgically removed postmortem, perfused, small pieces were cut from the right middle and lower lobes for research purpose, and stored in cold Perfadex® at 4 °C for no more than 12 h before processing. Ex planted lungs from emphysema lung transplant patients were stored in cold Perfadex® at 4 °C for no more than 12 h before the process. No lung explants were procured from prisoners.

Statistical analysis {#Sec22}
--------------------

All data are expressed as means ± s.e.m. Statistical significance was evaluated using Prism 6.0 software. One-way analysis of variance (ANOVA) was performed with post hoc Tukey's multiple comparison test, Mann--Whitney *U*-test, or Student's *t*-test applied as appropriate for comparisons between groups. A *P* \< 0.05 was considered significant.
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